WO2023133412A2 - Compositions ayant une action antivirale synergique et méthodes de traitement du coronavirus - Google Patents

Compositions ayant une action antivirale synergique et méthodes de traitement du coronavirus Download PDF

Info

Publication number
WO2023133412A2
WO2023133412A2 PCT/US2023/060101 US2023060101W WO2023133412A2 WO 2023133412 A2 WO2023133412 A2 WO 2023133412A2 US 2023060101 W US2023060101 W US 2023060101W WO 2023133412 A2 WO2023133412 A2 WO 2023133412A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
salts
magnesium
luteolin
manganese
Prior art date
Application number
PCT/US2023/060101
Other languages
English (en)
Other versions
WO2023133412A3 (fr
Inventor
Nitin Kumar Saksena
Thyago H.S. CARDOSO
Wael M. RABEH
Juliana Conrado FERREIRA
Original Assignee
Prophase Labs, Inc.
New York University In Abu Dhabi Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophase Labs, Inc., New York University In Abu Dhabi Corporation filed Critical Prophase Labs, Inc.
Publication of WO2023133412A2 publication Critical patent/WO2023133412A2/fr
Publication of WO2023133412A3 publication Critical patent/WO2023133412A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Definitions

  • the present invention relates to Luteolin compositions having synergistic antiviral activity and methods of their use in treating or ameliorating viral infections caused by coronaviruses such as SARS-CoV-2. More particularly, the present invention relates to the synergistic interaction of Luteolin and magnesium, manganese or zinc salts exhibiting enhanced antiviral action useful for treating or ameliorating “Middle East respiratory syndrome-related coronavirus” (such as MERS-CoV) and “Severe respiratory syndrome-related coronaviruses” (such as SARS-CoV-1 and SARS-CoV-2).
  • MERS-CoV Middle East respiratory syndrome-related coronavirus
  • Severe respiratory syndrome-related coronaviruses such as SARS-CoV-1 and SARS-CoV-2
  • Respiratory syndrome-related coronaviruses are a group of related betacoronaviruses, a genus in the subfamily Orthocoronavirinae, in the family Coronaviridae, order Nidovirales, and realm Riboviria. They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry.
  • the name coronavirus is derived from the Latin corona, meaning "crown" or "halo", which refers to the characteristic appearance pronounced of a solar corona around the virions (virus particles) when viewed under two-dimensional transmission electron microscopy, due to the surface being covered in club- shaped protein spikes.
  • betacoronavirus genome is similar to that of other Coronaviruses, with an ORFlab replicase polyprotein (rep, pplab) preceding other elements. This polyprotein is cleaved into many nonstructural proteins (including a SC- like protease - 3CLpro).
  • SARS-CoV-1 was identified in 2002 in Hong Kong resulting in several thousand deaths, but did not result in pandemic. But in December 2019, a highly aggressive and lethal form of infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, the capital of China's Hubei province, which has successfully spread globally, resulting in the coronavirus pandemic ongoing since 2019.
  • This pandemic is characterized by the emergence of multiple infectious variants (Alpha, Beta, Gamma, Delta and Omicron), faster spread, and greater infectious potential than its previous counterpart SARS-CoV-1 that emerged in 2003.
  • the disease has been given the name Coronavirus disease 2019 or COVID-19.
  • Common symptoms include fever, cough, and shortness of breath.
  • Other symptoms may include muscle pain, sputum production, diarrhea, sore throat, loss of smell, and abdominal pain. While the majority of cases result in mild symptoms, some progress to bilateral pneumonia and multi-organ failure.
  • COVID-19 has resulted in 270,430,963 infections, 5,322,092 deaths, and 243,147,220 recoveries globally.
  • SARS-CoV-2 is a positive-sense single-stranded RNA virus with approximately 29,900 nucleotides. Similar to the genome of other betacoronaviruses, SARS-CoV-2’ s genome contains two flanking untranslated regions (UTRs) and a single long open reading frame encoding a polyprotein. The 5'-terminal two- thirds of the genome encodes a polyprotein, pplab, which is further cleaved into 16 nonstructural proteins that are involved in genome transcription and replication. The 3' terminus encodes structural proteins, including envelope glycoproteins spike (S), envelope (E), membrane (M) and nucleocapsid (N).
  • S envelope glycoproteins spike
  • E envelope
  • M membrane
  • N nucleocapsid
  • the open reading frame, ORFlab of the viral genome is translated into a polyprotein (the orflab polyprotein having 7096 amino acid residues), from which sixteen non-structural proteins (Nspl-Nspl6), including the RNA-dependent RNA polymerase (RdRp, Nspl2), helicase (Nspl3), papain-like protease (Nsp3) and SC-like proteinase (3CL/?ro, main protease or M/?ro, Nsp5), among other Nsps involved in the transcription and replication of the virus, are released by extensive proteolytic processing. This is primarily achieved by the 306- amino acid 3C-like protease (3CLpro orMpro), a Cys protease, which is the main protease of the virus.
  • SARS-CoV-2 is the official name of the virus responsible for the COVID-19 pandemic, which has resulted in thousands of deaths worldwide and unprecedented levels of economic and social disruption. In the United States alone, well over 800,000 deaths have been attributed to COVID-19, with 50 million total infections since 2019, 40 million recoveries and 9 million active cases currently, as of December 14, 2021 (Worldometer Coronavirus, 2021). The virus was previously referred to as the “Wuhan virus”, “Wuhan coronavirus”, “China coronavirus”, “novel coronavirus” and subsequently “2019-nCoV”. The “SARS” part of the name refers to the new coronavirus’ genetic link to the virus that caused the 2003 SARS outbreak.
  • the virus is highly contagious and has a relatively high mortality rate in comparison to its genetically-related counterpart SARS-CoV-1 that emerged in 2003.
  • the pandemic has resulted in severe social distancing, stay at home orders and other measures to mitigate spread of the virus, which have resulted in significant disruptions of social and economic activity worldwide.
  • Several variants (Alpha, Beta, Gamma, Delta and Omicron) have been identified since the pandemic began, with some having high transmissibility, high infectious potential and disease altering ability.
  • SARS-CoV-2 and other coronaviruses
  • Efforts to develop treatments for SARS-CoV-2 has focused on vaccination, which now requires third or subsequent boosters, including bivalent boosters to better protect against later-developed variants.
  • Many oral antivirals have not proven effective in the current pandemic and have given variable results.
  • the present invention may provide important treatment options for COVID-19 patients, including those exposed to the virus by household contacts, those with diagnosed infections treated in the outpatient setting, and those hospitalized with moderate to severe infection.
  • the present invention is based on the recognition of the surprising synergism of Luteolin when combined with one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts (or a combination thereof), in particular in cooperating to enhance the antiviral activity of Luteolin against coronaviruses such as SARS-CoV-2.
  • compositions disclosed herein have been found to demonstrate enhanced antiviral activity against coronavirus, such as but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • the compositions have been found to exhibit suppression of at least one of Nsp5 (Mpro) of SARS-CoV-2 and PL/?ro of SARS-CoV-2.
  • another aspect of the present invention provides a method for inhibiting replication of a virus, for example, in an infected individual. The method comprises the step of suppressing a first viral protease, a second viral protease or both the first viral protease and the second viral protease.
  • the first and second viral proteases may be Nsp5 (M/?ro) of SARS-CoV-2 and PL/?ro of SARS- CoV-2 suppressed by administration of the compositions comprising Luteolin or a pharmaceutically acceptable salt thereof; and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts, and combinations thereof.
  • the present invention provides a composition comprising: Luteolin or a pharmaceutically acceptable salt thereof; and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts, and hydrates and combinations thereof, wherein the one or more salts enhances the antiviral activity of Luteolin against coronavirus.
  • Embodiments include the following, alone or in any combination.
  • the composition may comprise Luteolin or a pharmaceutically acceptable salt thereof; and one or more magnesium salts.
  • the composition may comprise Luteolin or a pharmaceutically acceptable salt thereof; and one or more zinc salts.
  • the composition may comprise Luteolin or a pharmaceutically acceptable salt thereof; and one or more manganese salts.
  • the composition may comprise Luteolin or a pharmaceutically acceptable salt thereof, one or more magnesium salts, and one or more zinc salts.
  • the composition may comprise Luteolin or a pharmaceutically acceptable salt thereof, one or more manganese salts, and one or more zinc salts.
  • the one or more magnesium salts, zinc salts, and manganese salts may have anions selected from the group consisting of acetate, bromide, chloride, citrate, decanoate, edetate, esylate, fumarate, gluceptate, gluconate, glutamate, glycinate, glycolate, glycollylarsanilate, hexanoate, hydrabamine, hydroxynaphthoate, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl sulfate, mucate, napsylate, nitrate, octanoate, oleate, oxide, palmoate, pantothenate, phosphate, polygalacturonate, propionate, salicylate, ste
  • the one or more manganese salts may be selected from the group consisting of manganese chloride, manganese sulfate, and manganese sulfate monohydrate.
  • the one or more zinc salts may be selected from the group consisting of zinc chloride, zinc sulfate, and zinc oxide.
  • composition may further comprise vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • composition may further comprise one or more additional components selected from the group consisting of a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, a diluent, and any combination thereof.
  • the composition may be in a dosage form selected from the group consisting of a capsule, a cachet, a pill, a tablet, a powder, a granule, a pellet, a bead, a particle, a troche, a lozenge, and a gel.
  • composition may be a therapeutic supplement.
  • the composition may be a pharmaceutical composition.
  • composition is useful for treating an individual infected by coronavirus; such as SARS-CoV-2 or variant thereof; or such as Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • coronavirus such as SARS-CoV-2 or variant thereof; or such as Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • compositions comprising Luteolin or a pharmaceutically acceptable salt thereof; one or more magnesium salts or hydrates thereof; and one or more manganese salts or hydrates thereof; wherein the one or more magnesium salts and the one or more manganese salts enhance the antiviral activity of Luteolin.
  • Embodiments of the composition include the following, alone or in any combination.
  • the one or more magnesium salts may be selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium glycinate and magnesium citrate.
  • the one or more manganese salts may be selected from the group consisting of manganese chloride, manganese sulfate, and manganese sulfate monohydrate.
  • the composition exhibits suppression of a first viral protease and suppression of a second viral protease.
  • the first viral protease may be Nsp5 (M/?ro) of SARS-CoV-2.
  • the second viral protease may be PL/?ro of SARS-CoV-2.
  • composition may further comprise vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • composition may further comprise one or more additional components selected from the group consisting of a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, a diluent, and any combination thereof.
  • the composition may be in a dosage form selected from the group consisting of a capsule, a cachet, a pill, a tablet, a powder, a granule, a pellet, a bead, a particle, a troche, a lozenge, and a gel.
  • composition may be a therapeutic supplement.
  • the composition may be a pharmaceutical composition.
  • composition is useful for treating an individual infected by coronavirus; such as SARS-CoV-2 or variant thereof; or such as Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • coronavirus such as SARS-CoV-2 or variant thereof; or such as Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • a method for increasing the antiviral potency of Luteolin.
  • the method includes preparing a composition comprising Luteolin (or a pharmaceutically acceptable salt thereof) and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts (or a combination thereof) as described above, administering a therapeutically effective amount to a human or animal of a composition comprising Luteolin and at least one of magnesium salts, manganese salts, zinc salts (or a combination thereof).
  • the term “therapeutically effective amount” as used herein means a nontoxic but sufficient amount of the corresponding compound to provide the desired effect.
  • the present invention provides a method of treating or ameliorating coronavirus.
  • the method comprises administering to an individual in need thereof a composition containing a therapeutically effective amount of Luteolin or a pharmaceutically acceptable salt thereof and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts, and a combination thereof, as described above.
  • the method comprises administering a therapeutically effective amount of a composition comprising Luteolin or a pharmaceutically acceptable salt thereof; and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts, and hydrates and combinations thereof, as described above.
  • Embodiments of the method included the following, alone or in any combination.
  • the method is useful for treating an individual infected by coronavirus; such as SARS-CoV-2 or variant thereof; or such as Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • coronavirus such as SARS-CoV-2 or variant thereof; or such as Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • the composition exhibits suppression of a first viral protease and suppression of a second viral protease.
  • the first viral protease may be Nsp5 (Mpro) of SARS-CoV-2.
  • the second viral protease may be PL/?ro of SARS-CoV-2.
  • composition inhibits replication of the coronavirus in the individual.
  • the one or more magnesium salts, zinc salts, and manganese salts may have anions selected from the group consisting of acetate, bromide, chloride, citrate, decanoate, edetate, esylate, fumarate, gluceptate, gluconate, glutamate, glycinate, glycolate, glycollylarsanilate, hexanoate, hydrabamine, hydroxynaphthoate, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl sulfate, mucate, napsylate, nitrate, octanoate, oleate, oxide, palmoate, pantothenate, phosphate, polygalacturonate, propionate, salicylate, stearate, subacetate, succinate, sulfate, tartrate, teoclate, isethionate, tosylate,
  • the composition may comprise one or more magnesium salts or hydrates thereof; and one or more manganese salts or hydrates thereof.
  • the composition may include one or more magnesium salts selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium glycinate and magnesium citrate.
  • the composition may include one or more manganese salts are selected from the group consisting of manganese chloride, manganese sulfate, and manganese sulfate monohydrate.
  • the composition may include one or more zinc salts selected from the group consisting of zinc chloride, zinc sulfate, and zinc oxide.
  • composition may further comprise vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • the composition may comprise a unit dose comprising 75-100 mg of Luteolin.
  • the composition may further comprise 200 to 600 mg of magnesium chloride; 2 to 10 mg of manganese sulfate monohydrate and 5 to 10 mg of zinc oxide.
  • the composition may further comprise 1000- 2000 mg of vitamin C.
  • the composition may further comprise 1000 International Units (IU) of vitamin D3.
  • the composition may be in a dosage form selected from the group consisting of a capsule, a cachet, a pill, a tablet, a powder, a granule, a pellet, a bead, a particle, a troche, a lozenge, and a gel.
  • composition may further comprise one or more additional components selected from the group consisting of a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, a diluent, and any combination thereof.
  • composition may be an over-the-counter therapeutic supplement.
  • the composition may be a pharmaceutical composition.
  • the composition may be administered in the form of a tablet, the tablet comprising 5-10% of the composition; 80% of fillers, disintegrants, lubricants, glidants, and/or binders; and 10% of additives capable of providing easy disintegration, disaggregation, and dissolution of the tablet in the stomach or the intestine of the individual.
  • the one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts and a combination thereof, is present in an amount effective for cooperating to enhance the antiviral activity of Luteolin against coronavirus.
  • the coronavirus is SARS-CoV-2 or variant thereof.
  • the coronavirus is Severe Acute Respiratory Syndrome-Corona Virus 1 (SARS-CoV-1), Middle East Respiratory Syndrome virus (CoV-MERS), human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • the individual has been diagnosed with COVID-19. BRIEF DESCRIPTION OF THE DRAWINGS
  • Figure 1A shows chemical structures of compounds tested as possible inhibitors of the SARS-CoV-2 protease enzyme 3CL/?ro The reactions were done at 30°C in 50 mM Hepes, 150 mM NaCl, 1 mM TCEP, 1 mM EDTA in 20% DMSO.
  • Figure IB shows a bar plot of the inhibition of 3CL/?ro or M/VY> by the compounds shown in Figure 1A.
  • Figures 2A-2D show aspects of the characterization of the inhibition pattern of Luteolin against 3CL/?ro or Mpro enzyme of the SARS-CoV-2.
  • Figure 2A shows the ICso curve activities of luteolin toward 3CL/?ro SARS-CoV-2.
  • Figure 2B shows double-reciprocal plots exhibiting competitive inhibition by luteolin was obtained upon varying the Luteolin concentration 40 pM, 95 pM, 170 pM, 225 pM, 300 pM, and 400 pM at several fixed concentrations of the peptide substrate 50 pM, 80 pM, 120 pM, 300 pM, and 400 pM .
  • Figure 2C shows ICso calculated from antiviral cell-based assay.
  • Figure 2D shows the titration of Luteolin at concentrations of 125uM, 250uM, 500uM and lOOuM against the whole virus in a cellular assay.
  • Figures 3A-3I show aspects of the determination of the ICso of Luteolin in combination with various metal ions.
  • Figures 3A-3C shows titration of chloride salts of zinc, manganese, and magnesium to determine the ICso values of the different metal ions against Mpro from SARS-CoV-2.
  • Figure 3D-3F shows the ICso of zinc, manganese, and magnesium was determined in the presence of luteolin that was kept fixed at 90 pM. The ICso of manganese, and magnesium decreased in the presence of luteolin, but it did not change with zinc.
  • Figure 3G-3I shows the ICso of luteolin was determined in the presence of different metal ions to further test their synergetic effect.
  • Figures 4A-4I show aspects of the determination of the ICso of Luteolin in combination with various metal ions.
  • Figures 4A-4C show titration of sulfate salts of zinc, manganese, and magnesium to determine the ICso values of the different metal ions against Mpro from SARS-CoV-2.
  • Figures 4D-4F show the ICso of zinc, manganese, and magnesium was determined in the presence of luteolin that was kept fixed at 90 pM. The ICso of manganese, and zinc decreased in the presence of luteolin, but increased with magnesium.
  • Figures 4G-4I show the ICso of luteolin determined in the presence of different metal ions to further test their synergetic effect.
  • Figures 5A-5C show aspects of the thermodynamic stability of Mpro.
  • Figure 5A shows DSC thermal scans of Mpro in the absence of luteolin (black line and presence of 25 pM (red line), 50 pM (blue light), 100 pM (green) and 250 pM (dark blue) luteolin acquired at pH 7.0 and 20% (v/v) DMSO. The sample was heated at a rate of 1 ,0°C/min.
  • Figure 5B shows a bar plot of AH cal calculated from the area under the thermographic peak in absence and presence of luteolin.
  • Figures 6A and 6B show aspects of the docking of Mpro with Luteolin in the catalytic active site.
  • Figure 6A shows the interaction between the luteolin and the amino acids from catalytic site.
  • Figure 6B shows the competitive interaction between the substrate and luteolin by the catalytic pocket.
  • Figures 7A and 7B show aspects of molecular docking results for 3CL/?ro with the peptide substrate, in absence and presence of Luteolin.
  • Figures 7A and 7B show aspects of docking representation of the 3CL/?ro substrate (blue) interacting with the 3CL/?ro dyad amino acids (red sticks) and other active site amino acids (red surface).
  • Figures 8A and 8B show aspects of dynamic simulation for 3CL/?ro with Luteolin in the catalytic active site.
  • Figure 8A shows RMSD variations for the 50 ns molecular dynamics simulation for the single complex between luteolin and 3CL/?ro, as well as with luteolin and 3CLpro structure complexed with substrate.
  • Figure 8B shows 3CL/?ro active site amino acids are indicated with black arrows, * indicates catalytic dyad amino acid.
  • Figure 9 shows aspects of protein cluster highlighting interactions between Nsp5 (3CL/?ro) with core proteins, their first-degree interactions, as well as the first-degree interactions for Luteolin.
  • the largest circles correspond to central proteins (Hub -bottleneck- black hand pointing, bottleneck- red arrow), these interactions were also highlighted with the wide and gray connectors.
  • Smaller circles correspond to second degree interactions (2 nd Nsp5 neighborhood) with Nsp5.
  • Proteins with first-degree interaction with Luteolin are represented with an *.
  • the solid red connectors highlight pathways that can connect Luteolin to Nsp5, white the red dotted connector represents the inhibitory potential of Nsp5 by Luteolin.
  • compositions having synergistic antiviral activity against coronaviruses such as such as SARS-CoV-2 or variant thereof, SARS-CoV-1, CoV-MERS, human HCoV-229E, HCoV-OC43, HCoV-NL63 or HCoV-HKUl.
  • the composition comprises Luteolin and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts and a combination thereof.
  • the inventors have surprisingly found that combinations of Luteolin with these metal salts have enhanced effectiveness at inhibiting proteases that cause replication of coronavirus, such as but not limited to the SARS-CoV-2 virus.
  • the present invention provides enhanced antiviral activity compared to Luteolin alone.
  • the disclosure demonstrates that combinations of Luteolin and magnesium salts, zinc salts, manganese salts and any combination of thereof were surprisingly effective at inhibiting 3CL/?ro or Mpro and PL/?ro proteases of SARS-CoV-2.
  • the one or more magnesium salts, zinc salts, manganese salts may be selected from acetate, bromide, chloride, citrate, decanoate, edetate, esylate, fumarate, gluceptate, gluconate, glutamate, glycinate, glycolate, glycollylarsanilate, hexanoate, hydrabamine, hydroxynaphthoate, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl sulfate, mucate, napsylate, nitrate, octanoate, oleate, oxide, palmoate, pantothenate, phosphate, polygalacturonate, propionate, salicylate, stearate, subacetate, succinate, sulfate, tartrate, teoclate, isethionate, tosylate, triethii
  • magnesium salts are magnesium chloride, magnesium sulfate, magnesium glycinate or magnesium citrate.
  • the manganese salts are manganese chloride, manganese sulfate, or manganese sulfate monohydrate.
  • the preferred zinc salts are zinc chloride, zinc sulfate, Zinc sulfate heptahydrate or zinc oxide.
  • Figure IB shows a bar plot of the inhibition of 3CL/?ro (Mpro) by the compounds shown in Figure 1A, compared to a control that was not treated with a test compound (100%).
  • the plot summarizes the inhibition exhibited by 25 pM of the different inhibitors against Mpro- SARS-CoV-2, and shows that Luteolin, Pl l in Figure 1A, was the most effective of the compounds tested at inhibiting 3CL/?ro (Mpro) (solid bar).
  • the reactions were done at 30°C in 50 mM Hepes, 150 mM NaCl, 1 mM TCEP and 1 mM EDTA in 20% DMSO.
  • Figures 2A-2D show aspects of the characterization of the inhibition pattern of Luteolin against 3CL/?ro SARS-CoV-2.
  • Figure 2A shows ICso curve activities of Luteolin toward 3CL/?ro SARS-CoV-2.
  • Figure 2B shows double-reciprocal plots exhibiting competitive inhibition by Luteolin was obtained upon varying the Luteolin concentration 40 pM, 95 pM, 170 pM, 225 pM, 300 pM, and 400 pM at several fixed concentrations of the peptide substrate 50 pM, 80 pM, 120 pM, 300 pM, and 400 pM.
  • proteolytic rates were measured in 50 mM Hepes, 150 mM NaCl, 1 mM TCEP, and 1 mM EDTA in the presence of 20% DMSO at 30 °C.
  • Figure 2C shows the IC50 calculated from the antiviral assay, indicating that Luteolin provides an IC50 of 90 + 11 pM. Luteolin was titrated into Hek293T cells previously infected with SARS-CoV-2.
  • Figure 2D shows bright field images of the assays.
  • Figures 3A-3H show aspects of the determination of the IC50 of Luteolin in combination with various metal ions.
  • Figures 3A-3C are plots showing titration of chloride salts of zinc, manganese, and magnesium to determine the IC50 values of the different metal ions against Mpro from SARS-CoV-2.
  • Figures 3D-3F show the IC50 of zinc chloride, manganese chloride, and magnesium chloride determined in the presence of Luteolin that was kept fixed at 90 pM.
  • the IC50 of manganese chloride, and magnesium chloride decreased in the presence of Luteolin, but it did not change with zinc chloride.
  • Figures 3G-3I illustrate the determination of the IC50 of Luteolin in the presence of different metal ions to further test their synergetic effect.
  • the presence of 2.3 mM of manganese did not affect the IC50 of Luteolin.
  • the addition of 1.3 mM zinc and 24 mM magnesium decrease the IC50 of Luteolin by 4-fold and 50-fold, respectively, with IC50 values of Luteolin decreased from 78.0 ⁇ 3.0 pM to 21.2 ⁇ 0.4 pM and 1.5 ⁇ 0.1 pM in the presence of zinc and manganese, respectively.
  • the Mpro enzyme and peptide substrate concentrations were fixed at 3 pM and 60 pM, respectively.
  • Figures 4A-4I show aspects of the determination of the IC50 of Luteolin in combination with various metal ions.
  • Figures 4A-4C show titration of sulfate salts of zinc, manganese, and magnesium to determine the IC50 values of the different metal ions against Mpro from SARS-CoV-2. Similar to panels in Figures 4A-4C, the IC50 of zinc, manganese, and magnesium was determined in the presence of Luteolin that was kept fixed at 90 pM ( Figures 4D-4F). The IC50 of manganese, and zinc decreased in the presence of Luteolin, but increased with magnesium.
  • Figures 4G-4I show the determination of the IC50 of Luteolin in the presence of different metal ions to further test their synergetic effect.
  • the Mpro and peptide substrate concentrations were fixed at 3 pM and 60 pM, respectively.
  • Figures 5A-5C show aspects of the thermodynamic stability of Mpro.
  • Figure 5A shows differential scanning calorimetry (DSC) thermal scans of Mpro in the absence of Luteolin (black line) and presence of 25 pM (red line), 50 pM (blue line), 100 pM (green line) and 250 pM (dark blue line) Luteolin acquired at pH 7.0 and 20% (v/v) DMSO. The sample was heated at a rate of 1.0°C/min.
  • Figure 5B shows a bar plot of AHcai calculated from the area under the thermographic peak in absence and presence of Luteolin.
  • Figures 6A and 6B show aspects of the docking of Mpro with Luteolin in the catalytic site.
  • Figure 6A shows the interaction between the Luteolin and the amino acids from the catalytic site.
  • Figure 6B shows the competitive interaction between the substrate and Luteolin by the catalytic pocket.
  • Figures 7A and 7B show aspects of molecular docking results for 3CL/?ro with the peptide substrate, in absence and presence of Luteolin.
  • Figure 7A is a docking representation of the 3CL/?ro substrate (blue) interacting with the 3CL/?ro dyad amino acids (red sticks) and other active site amino acids (red surface).
  • Figure 7A is a docking representation of 3CL/?ro substrate (blue) with Luteolin (green), interacting with the 3CL/?ro dyad amino acids (red sticks) and other active side amino acids (red surface).
  • Figures 8A and 8B show aspects of dynamic simulation for 3CL/?ro with Luteolin in the catalytic site.
  • Figure 8A shows RMSD variations for the 50 ns molecular dynamics simulation for the single complexes between Luteolin and 3CL/?ro, as well as with Luteolin and 3CL/?ro structure complexed with substrate.
  • Figure 8B 3CL/?ro active site amino acids are indicated with black arrows, catalytic dyad amino acids are indicated with an asterisk (*).
  • Figure 9 shows aspects of protein clustering between Nsp5 (3CLpro) with core proteins, highlighting interactions between Nsp5 (3CL/?ro) with core proteins, their first-degree interactions, as well as the first-degree interactions for Luteolin.
  • the largest circles correspond to central proteins (Hub-bottleneck- black hand pointing, bottleneck- red arrow). These interactions were also highlighted with the wide and gray connectors. Smaller circles correspond to second degree interactions (second Nsp5 neighborhood) with Nsp5. Proteins with first-degree interaction with Luteolin are represented with an *.
  • the solid red connectors highlight pathways that can connect Luteolin to Nsp5, while the red dotted connector represents the inhibitory potential of Nsp5 by Luteolin.
  • compositions or combinations may further comprise vitamin C, vitamin D and/or vitamin B12.
  • Vitamin C is beneficial for the health of leukocytes, a type of white blood cells that help fight infections. Supplement of 1000 mg twice every day is recommended normally.
  • Vitamin D may play a considerable role in reducing inflammation and enhancing immunity to coronaviruses such as SARS-CoV-2.
  • Vitamin B12 (cobalamin/cyanocobalamin) may regulate chemokine/cytokine formation and mediate the communication among immune cells in pathophysiological pathways and thus protect against various bacterial and viral infections, including CO VID-19.
  • Combination of Luteolin with Vitamin D, Vitamin C and vitamin B12 may provide better immune support, than Luteolin alone, needed during viral infections.
  • Embodiment 1 A composition or combination comprising Luteolin or a pharmaceutically acceptable salt thereof; and one or more salts selected from the group consisting of magnesium salts, manganese salts, zinc salts, and combinations thereof.
  • Embodiment 2 The composition or combination of Embodiment 1 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment s The composition or combination of Embodiment 1 comprising Luteolin and a magnesium salt.
  • Embodiment 4 The composition or combination of Embodiment 3 wherein the magnesium salt comprises magnesium chloride, magnesium glycinate or magnesium citrate.
  • Embodiment 5 The composition or combination of Embodiment 1 comprising Luteolin and magnesium chloride.
  • Embodiment 6 The composition or combination of Embodiment 1 comprising
  • Embodiment 7 The composition or combination of Embodiment 1 comprising
  • Embodiment 8 The composition or combination of Embodiment 3 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment 9 The composition or combination of Embodiment 8 comprising
  • Embodiment 10 The composition or combination of Embodiment 8 comprising
  • Embodiment 11 The composition or combination of Embodiment 8 comprising
  • Embodiment 12 The composition or combination of Embodiment 8 comprising
  • Embodiment 13 The composition or combination of Embodiment 8 comprising
  • Luteolin a magnesium salt, vitamin C, vitamin D and vitamin B12.
  • Embodiment 14 The composition or combination of Embodiment 1 comprising
  • Embodiment 15 The composition or combination of Embodiment 1 comprising
  • Embodiment 16 The composition or combination of Embodiment 1 comprising
  • Embodiment 17 The composition or combination of Embodiment 1 comprising
  • Embodiment 18 The composition or combination of Embodiment 10 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment 19 The composition or combination of Embodiment 18 comprising
  • Embodiment 20 The composition or combination of Embodiment 18 comprising
  • Embodiment 21 The composition or combination of Embodiment 18 comprising Luteolin, zinc chloride or zinc oxide, and vitamin B12.
  • Embodiment 22 The composition or combination of Embodiment 18 comprising Luteolin, zinc chloride or zinc oxide, and vitamin C and vitamin D.
  • Embodiment 23 The composition or combination of Embodiment 18 comprising Luteolin, zinc chloride or zinc oxide, and vitamin C, vitamin D and vitamin B12.
  • Embodiment 24 The composition or combination of Embodiment 1 comprising a manganese salt.
  • Embodiment 25 The composition or combination of Embodiment 24 wherein the manganese salt comprises manganese sulfate.
  • Embodiment 26 The composition or combination of Embodiment 24 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment 27 The composition or combination of Embodiment 26 comprising
  • Embodiment 28 The composition or combination of Embodiment 26 comprising
  • Embodiment 29 The composition or combination of Embodiment 26 comprising
  • Embodiment 30 The composition or combination of Embodiment 26 comprising
  • Embodiment 31 The composition or combination of Embodiment 26 comprising
  • Embodiment 32 The composition or combination of Embodiment 1 comprising a magnesium salt and a manganese salt.
  • Embodiment 33 The composition or combination of Embodiment 32 wherein the magnesium salt comprises magnesium chloride, magnesium glycinate or magnesium citrate.
  • Embodiment 34 The composition or combination of Embodiment 32 wherein the magnesium salt comprises magnesium chloride.
  • Embodiment 35 The composition or combination of Embodiment 32 wherein the magnesium salt comprises magnesium glycinate.
  • Embodiment 36 The composition or combination of Embodiment 32 wherein the magnesium salt comprises magnesium citrate.
  • Embodiment 37 The composition or combination of Embodiment 32 wherein the manganese salt comprises manganese sulfate.
  • Embodiment 38 The composition or combination of Embodiment 3 comprising Luteolin, magnesium chloride and manganese sulfate.
  • Embodiment 39 The composition or combination of Embodiment 3 comprising Luteolin, magnesium glycinate and manganese sulfate.
  • Embodiment 40 The composition or combination of Embodiment 3 comprising
  • Embodiment 41 The composition or combination of Embodiment 32 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment 42 The composition or combination of Embodiment 41 comprising
  • Luteolin a magnesium salt, a manganese salt, and vitamin C.
  • Embodiment 43 The composition or combination of Embodiment 41 comprising
  • Luteolin a magnesium salt, a manganese salt, and vitamin D.
  • Embodiment 44 The composition or combination of Embodiment 41 comprising
  • Luteolin a magnesium salt, a manganese salt, and vitamin B12.
  • Embodiment 45 The composition or combination of Embodiment 41 comprising
  • Luteolin a magnesium salt, a manganese salt, vitamin C and vitamin D.
  • Embodiment 46 The composition or combination of Embodiment 41 comprising
  • Luteolin a magnesium salt, a manganese salt, vitamin C, vitamin D and vitamin B12.
  • Embodiment 47 The composition or combination of Embodiment 1 comprising a magnesium salt, a manganese salt and a zinc salt.
  • Embodiment 48 The composition or combination of Embodiment 47 wherein the magnesium salt comprises magnesium chloride, magnesium glycinate or magnesium citrate.
  • Embodiment 49 The composition or combination of Embodiment 47 wherein the magnesium salt comprises magnesium chloride.
  • Embodiment 50 The composition or combination of Embodiment 47 wherein the magnesium salt comprises magnesium glycinate.
  • Embodiment 51 The composition or combination of Embodiment 47 wherein the magnesium salt comprises magnesium citrate.
  • Embodiment 52 The composition or combination of Embodiment 47 wherein the manganese salt comprises manganese sulfate.
  • Embodiment 53 The composition or combination of Embodiment 47 wherein the zinc salt comprises zinc chloride.
  • Embodiment 54 The composition or combination of Embodiment 47 wherein the zinc salt comprises zinc oxide.
  • Embodiment 55 The composition or combination of Embodiment 47 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment 56 The composition or combination of Embodiment 55 comprising Luteolin, a magnesium salt, a manganese salt, a zinc salt and vitamin C.
  • Embodiment 57 The composition or combination of Embodiment 41 comprising Luteolin, a magnesium salt, a manganese salt, a zinc salt and vitamin D.
  • Embodiment 58 The composition or combination of Embodiment 41 comprising Luteolin, a magnesium salt, a manganese salt, a zinc salt and vitamin B12.
  • Embodiment 59 The composition or combination of Embodiment 41 comprising
  • Luteolin a magnesium salt, a manganese salt, a zinc salt vitamin C and vitamin D.
  • Embodiment 60 The composition or combination of Embodiment 41 comprising
  • Embodiment 61 The composition or combination of Embodiment 1 comprising Luteolin, magnesium chloride, manganese sulfate, and zinc oxide.
  • Embodiment 62 The composition or combination of Embodiment 61 further comprising vitamin C, vitamin D, vitamin B12 or combinations thereof.
  • Embodiment 63 The composition or combination of Embodiment 1 that is a food supplement.
  • Embodiment 64 The composition or combination of Embodiment 1 that is a pharmaceutical composition.
  • Embodiment 65 The composition or combination of Embodiment 64 further comprising a pharmaceutically acceptable additive.
  • Embodiment 66 The composition or combination of Embodiment 64 further comprising a pharmaceutically acceptable carrier.
  • the embodiments described in this disclosure may be formulated with one or more pharmaceutically acceptable additives.
  • the additive may be a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, a diluent or dilutant, and/or combinations thereof.
  • Other pharmaceutically acceptable additives include sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, or similar oils, water or saline aqueous solutions, aqueous dextrose and glycerol solutions.
  • the pharmaceutically acceptable additive useful for formulating a dosage form comprising the composition of this disclosure will depend, among other factors, on the elected administration route.
  • the combination may be administered in a dosage form selected from the group consisting of a capsule, a cachet, a pill, a tablet, a powder, a granule, a pellet, a bead, a particle, a troche, a lozenge, and a gel.
  • the composition may be in solid or liquid form for oral administration.
  • Solid forms include tablets, caplets, pill, capsules, gelcaps, powders, granules, gummies and the like.
  • a tablet or pill is usually a compressed preparation that may contain, for example but not limitation, 5-10% of the Luteolin and metal salts; 80% of fillers, disintegrants, lubricants, glidants, and/or binders; and 10% of compounds that provide easy disintegration, disaggregation, and dissolution of the tablet in the stomach or the intestine.
  • the dissolution time can be modified for a rapid effect or for sustained release.
  • Pills can be coated with sugar, varnish, shellac, or wax to disguise the taste.
  • a caplet is a compressed mixture of ingredients, similar to a tablet, which is formed into a capsule shape. It often has a film or gelatin coating to mask the taste and make it easier to swallow.
  • Capsules generally comprise hard shells that can contain powders or granules, or liquids in some embodiments.
  • a soft gel capsule or gelcap comprises a thicker, softer shell that may be easier to swallow. Gelcaps often comprise liquid or paste compositions inside the gelatin shell.
  • Gummies are chewable formulations comprising the active ingredients in a chewable gelatin base. They may come in a variety of flavors, colors, and shapes and may be desirable for a subject that may not like swallowing pills or capsules.
  • the composition may be in the form of a biodegradable capsule containing the composition. In one embodiment, the composition is in the form of a supplement. In another embodiment, it is in the form of a pharmaceutical composition. In another embodiment, the compositions may be formulated with liposomes, polymeric micelles, microspheres or nanoparticles
  • the composition can be formulated as a powder that can be added to a liquid, for example a beverage, to prepare a drinkable solution or suspension of the combination.
  • a liquid for example a beverage
  • Liquid formulations may be formulated for oral, topical or percutaneous applications.
  • a unit dose is the amount of a medication administered to an individual in a single dose.
  • a unit dose for example may comprise 75-100 mg of Luteolin; 200 to 600 mg, such as 500 mg, of magnesium chloride; 2 to 10 mg, such as 3.5 mg, of manganese, as manganese sulfate monohydrate; and 5 to 10 mg, such as 7.5 mg, of zinc, as zinc oxide.
  • the unit dose may further comprise vitamin C, vitamin D and/or vitamin B12.
  • the unit dose may comprise 1000-2000 mg of vitamin C.
  • the unit dose may comprise 1000 International Units (IU) of vitamin D3.
  • compositions may be manufactured according to conventional methods known by the skilled person in the art.
  • the compositions may be prepared using standard methods such as those described or referred to in the US Pharmacopoeias and similar reference texts.
  • compositions of the present invention can be administered as a pharmaceutical composition or an over-the-counter therapeutic supplement, either of which comprises the composition described herein and one or more pharmaceutically acceptable additives.
  • the compounds for use according to the invention may be administered as the sole active ingredient or in combination with other active ingredients.
  • the compounds are used as the sole active ingredient.
  • the compounds are used in combination with other active ingredients.
  • the combination When the combination is in the form of a single composition, the ingredients present in the combination are always administered simultaneously. [00165] When the combination is in the form of several compositions (or units), each of them having at least one of the ingredients of the combination, the compositions or (units) may be administered simultaneously, sequentially or separately.
  • Simultaneous administration means that the ingredients or compositions (or units) are administered at the same time.
  • Sequential administration means that the ingredients or compositions (or units) are administered at different time points in a chronologically staggered manner.
  • Separate administration means that the ingredients or compositions (or units) are administered at different time points independently of each other.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition ayant une activité antivirale améliorée contre le coronavirus comprenant de la lutéoline ou un sel pharmaceutiquement acceptable de celle-ci, et un ou plusieurs sels choisis dans le groupe constitué de sels de magnésium, de sels de manganèse, de sels de zinc et de combinaisons de ceux-ci. Une méthode de traitement du coronavirus chez un individu comprend l'administration de la composition à l'individu.
PCT/US2023/060101 2022-01-05 2023-01-04 Compositions ayant une action antivirale synergique et méthodes de traitement du coronavirus WO2023133412A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263296750P 2022-01-05 2022-01-05
US202263296761P 2022-01-05 2022-01-05
US63/296,761 2022-01-05
US63/296,750 2022-01-05

Publications (2)

Publication Number Publication Date
WO2023133412A2 true WO2023133412A2 (fr) 2023-07-13
WO2023133412A3 WO2023133412A3 (fr) 2023-08-24

Family

ID=87074255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060101 WO2023133412A2 (fr) 2022-01-05 2023-01-04 Compositions ayant une action antivirale synergique et méthodes de traitement du coronavirus

Country Status (1)

Country Link
WO (1) WO2023133412A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318237T2 (de) * 2002-10-24 2008-12-18 Immupharm A/S Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
CN114126643A (zh) * 2019-05-28 2022-03-01 艾巴尔生态技术公司 包含溶菌酶的广谱抗菌药物制剂及其使用方法
BR112021024310A2 (pt) * 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
EP4009815A4 (fr) * 2019-09-12 2023-09-06 Nulixir Inc. Particules noyau-enveloppe à libération contrôlée et suspensions les comprenant
US11419847B2 (en) * 2020-04-10 2022-08-23 Matthias W. Rath Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants
US11883376B2 (en) * 2020-04-22 2024-01-30 Nadimpally Satyavarahala Raju Viral infection treatment with 5-aminolevulinic acid

Also Published As

Publication number Publication date
WO2023133412A3 (fr) 2023-08-24

Similar Documents

Publication Publication Date Title
TW589177B (en) Having improved antitussive effect drug preparations
ES2534245T3 (es) Formulaciones de suplemento antiviral
JP7085998B2 (ja) 抗レトロウイルス薬及び薬物動態学的エンハンサーを含む医薬組成物
KR20200131784A (ko) 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
KR20090113777A (ko) 불쾌한 맛을 은폐한 경구 조성물
WO2023133412A2 (fr) Compositions ayant une action antivirale synergique et méthodes de traitement du coronavirus
AU2018255954B2 (en) Combination therapy for use in treating retroviral infections
WO2021244481A1 (fr) Compositions et méthodes de traitement d'une infection au sras-cov-2
CN113521248A (zh) 一种益生菌活性肽在制备具有预防或治疗腹泻作用的药物、食品或保健品中的应用
JP6718293B2 (ja) 抗ウイルス剤及び抗ウイルス用食品組成物
KR102240693B1 (ko) 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물
TWI624264B (zh) 南洋山蘇水萃物的用途
US20240108678A1 (en) Anti-viral compositions
CN113730584B (zh) 双硫仑联合铜补充剂在制备抗rna病毒的药物中的应用
EP4275683A1 (fr) Composition pharmaceutique antivirale comprenant un inhibiteur de stéroïde sulfatase
US20220304947A1 (en) Compositions and methods for inhibiting proteolytic activation of viruses
US20220133858A1 (en) Pharmacological compositions for the treatment and prevention of coronavirus disease
WO2022034515A1 (fr) Composition de pipérine solubilisée et procédé associé
CN104784185B (zh) 奈韦拉平药物组合物及其制备方法
JP2008105950A (ja) 関節炎・関節症の為の経口投与組成物
CN1243764C (zh) 新型过氧二烯缩醛糖苷类衍生物及其制法和其药物组合物与用途
KR20230143964A (ko) 바이러스 감염증의 예방 또는 치료용 약학 조성물
CN116850192A (zh) 一种核苷类衍生化合物的药物组合物及其制备方法和用途
JP6565334B2 (ja) 固形製剤
KR20220120520A (ko) 인공지능 알고리즘으로 연구된 헬리케이즈 (Helicase, NSP13) 억제 활성을 갖는 화합물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737714

Country of ref document: EP

Kind code of ref document: A2